Merck (MRK) Tops Q1 EPS by 5c; Offers FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Merck Announces First-Quarter 2023 Financial Results
April 27, 2023 6:30 AM EDTFirst Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 15% KEYTRUDA Sales Grew 20% to $5.8 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24% GARDASIL/GARDASIL 9 Sales Grew 35% to $2.0 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 43% LAGEVRIO Sales Declined 88% to $392 Million; Excluding the Impact of Foreign Exchange, Sales Declined 87% GAAP EPS Was $1.11;... More
